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Introduction
Methytransferases were some of the first enzymes to evolve, as 
can be seen from a brief inspection of the entries for methyl-
transferases in archaea in PubMed (Protein Clusters). 
Furthermore, a search for nicotinamide N-methyltransferase 
(NNMT) returned 106 results for NNMT-related proteins (as 
of the date of writing) in EnsemblGenomes showing the pres-
ence of these enzymes in a wide variety of species, which 
includes both animals and plants.1 The N-methyltransferases 
comprise a group of some 30 or more enzymes which includes 
enzymes methylating amino groups of amino acids and amino 
acid residues in proteins, among which the latter class is his-
tone methyltransferase, an enzyme involved in gene regulation. 
The evolution of oxidised nicotinamide adenine dinucleotide 
(NAD+) synthesis and salvage,2–4 the phylogenic distribution 
of NAD+,5 and the linkage between NAD+ and adenosine 
triphosphate (ATP) synthesis have been explored as sequence 
data across many species have become available. These data 
have led to the conclusion that the emergence of new NAD+-
consuming enzymes increased and that NNMT probably 
emerged as a means of regulating levels of nicotinamide 
(NAM) within the cell, possibly so that NAM did not inhibit 
DNA repair.6,7
The Early History of NNMT
Methylation of a pyridine by a factor in human tissue was first 
described by His8 in 1884. Nevertheless, for most of the first 
half of the 20th century, the metabolic fate of NAM was 
unclear, with trigonelline often being proposed as its principal 
final outcome. This was because the means of distinguishing 
1-methylnicotinamide (MeNAM) from other compounds 
were not available. The conversion of NAM to MeNAM in 
human and animal tissues was shown to occur by the early 
1940s. Ellinger and Coulson9 described the excretion of 
MeNAM in human urine. That MeNAM is the primary uri-
nary excretion product of human NAM metabolism was shown 
by Ellinger and Abdel Kader.10 Further catabolism of MeNAM 
to pyridones was reported by Knox and Grossman11 and 
Holman and Wiegand.12 As early as 1941, Mann and Quastel13 
were exploring the interaction of NAM with S-adenosyl 
methionine (SAM). Again, in the 1940s, the major site of con-
version of NAM to MeNAM was the liver.14 The first detailed 
characterisation of a soluble protein enzyme capable of con-
verting NAM to MeNAM was conducted by Cantoni15 in 
1951 using extracts from rat and pig livers.
NNMT: Gene, Messenger RNA, and Protein 
(NNMT: EC 2.1.1.1)
The human NNMT gene is contained on a 55.5-kb stretch on 
the forward strand of the long arm of chromosome 11 
(11q23.1).16 The gene contains either 3 or 5 exons depending 
on the transcription start site (TSS) used to transcribe mes-
senger RNA (mRNA).16–18 Of the 2 TSSs, the TSS further 
from the translation initiation ATG codon (TSS1) gives rise to 
a 1867 base transcript involving 5 exons, whereas the 3′ TSS 
(TSS2) gives rise to a 1610 base transcript involving 3 
exons. Both transcripts give rise to the same translated 
sequence of 792 bases plus a TGA stop codon. Several other 
noncoding transcripts are also produced.18 The 5′ flanking 
region of the gene from TSS2 contains numerous response ele-
ments, revealed by the TFSearch programme.19 These include 
sites such as CdxA, GATA-1, CREB, CRE-BP, and AP-1 
sites, although there is no TAATA site near the TSS. Trans-
acting factors known to influence level of expression via tran-
scription include hepatocyte nuclear factor-1β,20 signal 
transducer and activator of transcription 3 (STAT3),21 trans-
forming growth factor β1 (TGF-β1),22 and androgens.23 
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Endogenous c-Jun, in addition to any effect on mRNA levels, 
influences exon splicing of the pre-mRNA in mammary 
cancer.24
DNA analyses of samples taken from human populations 
across the world have revealed several hundred single-nucleo-
tide polymorphisms across the gene and its flanking regions.18 
Nevertheless, no polymorphism in the exons of the 3-exon 
gene itself or in the immediate 5′ flanking region of TSS1 was 
found to be related to the level of protein expression.25 Even so, 
numerous genetic polymorphisms not affecting the mRNA 
and protein structures have been reported to be linked to age-
ing26; cancer, eg, acute lymphoblastic leukaemia in children 
(intervening sequence – 151)27,28 and oral squamous cell carci-
noma29; and other diseases, eg, congenital heart defects in chil-
dren (rs694539)30 and bipolar disorder (rs694539).31
The NNMT protein comprises a single 264-amino-acid 
polypeptide of molecular weight 29 574.02 g/mol. It was iso-
lated first from human liver homogenates by Aksoy et  al.17 
Where the molecular weight has been investigated using 
sodium dodecyl sulphate polyacrylamide gel electrophoresis/
western blotting, most reports do not state any difference from 
the figure of approximately 26000. Nevertheless, Lim et  al32 
describe a number of posttranslational modifications to the 
protein in gastric cancer tissue. The primary sequence of the 
enzyme is closely related to that of 2 other N-methyltransferases, 
indolethylamine-N-methyltransferase and phenylethanola-
mine N-methyltransferase. These 3 enzymes form a subgroup 
within the large N-methyltransferase family.
The tissue with the highest level of expression in humans 
is the liver, as noted above.17 Other sites of high expression 
include the kidney and lung17 and white adipose tissue.33 
Expression of NNMT within the brain is largely confined to 
neurons and is highly regional. Sites of expression with the 
brain include the dopaminergic neurons of the substantia 
nigra and neurons in the granular layer of the cerebellum34 
and in the frontal cortex.35 Expression within astrocytes is 
detectable but at very low levels.36 Expression within the liver 
of normal individuals was said to have a bimodal distribution, 
with 25% of the population being high expressors and the 
remaining 75% being spread between moderate and low lev-
els of expression, with an approximately 5-fold difference 
between the highest and lowest expressors.37 In a study of 
mRNA sequences and protein levels isolated from sections 
of livers taken from 20 healthy individuals dying as a result of 
road traffic accidents or similar traumatic events, which were 
being used for liver transplantation, it was found that irre-
spective of the level of protein expression, all mRNAs had the 
same sequence. Furthermore, the protein expression followed 
a pattern of 1:2:1, high:intermediate:low ratio, in Hardy-
Weinberg equilibrium.38
Nicotinamide N-methyltransferase uses SAM as the methyl 
donor to methylate the target amino group of the substrate and 
yield S-adenosyl homocysteine (SAH) which is converted to 
homocysteine and adenosine.39 As might be expected, the 
3-dimensional (3D) structure of NNMT contains the charac-
teristic N-methyltransferase fold, where the substrate and the 
SAM cofactor are embedded deep within the molecule. The 
entrance to these sites is partially covered by a cap. This cap is 
formed by 2 α-helices near the N-terminus and a reverse 
β-hairpin spanning lysine residue 203 to serine residue 212.40 
The binding sites themselves are formed from 7 β-chains and 
5 α-helices, the SAM-binding site having 3 β-strands and 2 
α-helices, and the substrate-binding site having 4 β-strands 
and 2 α-helices with the 2 binding sites being separated by 1 
α-helix.40 In a crystallographic study by Peng et al, using NAM 
and SAH – the immediate product following donation of the 
methyl group of SAM – as ligands for the substrate and cofac-
tor-binding sites, respectively, the residues involved in binding 
of the substrate and cofactor were identified.41 The cofactor 
is in contact with more residues than is the substrate, which 
would tend to suggest that the cofactor is bound more strongly 
than the substrate. Tyrosine residues constitute a significant 
proportion of each of the binding sites. Figure 1 shows a ribbon 
cartoon of the human NNMT. Donation of the methyl group 
of SAM to NAM involves rearrangement of a major part of the 
protein’s 3D structure (residues 134-154). This is to bring the 
donor and substrate in close proximity to allow the transfer of 
the methyl group to occur.41
NNMT and MeNAM in Biological Fluids
Although NNMT is an intracellular enzyme, it is released into 
the bloodstream, presumably chiefly from the liver. The median 
serum NNMT concentration of 25 healthy donors was reported 
to be 165 ng/L.42 Other estimates of the serum concentration 
of MeNAM and urinary excretion of healthy humans are vari-
ously quoted as having a mean concentration of 96 ± 28 µmol/L 
(mean ± SD, N = 16) and a urinary excretion rate of 20 ± 5 
Figure 1. Ribbon cartoon of 3-dimensional structure of nicotinamide 
N-methyltransferase. Red denotes α-helix; blue, β-strand; grey, coil; and 
green, turn.
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µmol/24 hours (mean ± SD, N = 16)43 or a mean serum con-
centration of 150 µmol/L and a mean 24-hour excretion rate of 
48.8 µmol/24 hours.44 As stated above, the liver is the major 
site of expression. Whether the genetically determined level of 
NNMT expression in the liver influences the levels of MeNAM 
in readily available fluids was uncertain. Therefore, one of us 
(R.H.W.) conducted a study of NAM metabolite excretion of 
30 individuals in 8 family groups. The only metabolite of NAM 
that exhibited an excretion pattern resembling the expression 
pattern of high, intermediate, and low expression of NNMT in 
liver was MeNAM.45 The study was conducted over a 24-hour 
period, thus obviating any effect that the circadian rhythm of 
NAD+ synthesis might have on the results.46 Nicotinamide 
N-methyltransferase expression itself is not thought to have a 
circadian rhythm. Whether all tissues in the body follow the 
pattern of NNMT expression seen in the liver is unclear, but in 
healthy individuals leading a normal life, the pattern of 
MeNAM excretion does appear to follow that of hepatic 
NNMT expression. Nevertheless, the lack of biopsy material 
meant that the 2 parameters could not be correlated.
1-Methylnicotinamide is actively taken into and released 
from cells. The uptake process in rat liver was first described by 
Moseley et al,47 who characterised MeNAM/H+ exchange in 
basolateral vesicles. Subsequently, the proteins that perform 
these processes have been recognised as members of a large 
class of ubiquitously expressed organic anion transporters 
(OATs), in particular OATs 1-3, which are capable of trans-
porting a broad spectrum of ions.48,49
Ontogeny of NNMT
The ontogeny of the various enzymes of the phase 2 xenobiotic 
excretion system in mice has been elucidated in a study by Lu 
et al.50 They showed that NNMT mRNA in the liver was pre-
sent in only very low levels in prenatal animals. After birth, 
expression remained low until day 10, and thereafter, expres-
sion of the enzyme increased rapidly. By postnatal day 60, 
NNMT mRNA expression had reached its maximum. It would 
seem likely that a similar pattern of limited prenatal expression 
followed by rapidly increasing postnatal levels occurs in 
humans. Nevertheless, although in the neonatal animal NNMT 
appears to have limited expression, in the very earliest stage of 
human life, the enzyme does play a vital role. In human-naive 
embryonic stem cells, NNMT and MeNAM regulate pluripo-
tency where the enzyme consumes SAM, thus limiting histone 
methylation. Hence, the enzyme and its product play an impor-
tant role in regulating ‘the epigenetic landscape of the earliest 
steps in human development’.51
NNMT and Ageing
In a review of the interplay of genetics and epigenetic signals in 
the developing neocortex, Huffmann52 suggests that although 
genetics may be the dominant influence in early life, the influ-
ence of epigenetics may be significantly greater in the ageing 
process. This comes from work showing that caloric restriction 
influences DNA methylation, and hence ageing,53,54 and earlier 
work linking caloric restriction to NAM, NAD+, and sir-
tuins.55–57 The interplay of these factors has been reviewed 
extensively by Imai and Guarente.58 Importantly, from the 
point of view of this review, Schmeisser et  al show that the 
methylation of NAM, as well as that of DNA, plays a signifi-
cant role. They found that a low dose (1 µM) of MeNAM 
increased the life span of Caenorhabditis elegans, whereas a high 
dose (1 mM) had the opposite effect. In particular, they showed 
that the action of NAM was dependent on the conversion to 
MeNAM by this species’ equivalent of mammalian NNMT, 
not by NAM modulating histone deacetylation by the nema-
todal orthologue of sirtuin 1. Cloning human NNMT into the 
nematode also increased longevity. They went on to show that 
the ability of MeNAM to extend life was dependent on its 
oxidation to its pyridone derivatives. This oxidation step gener-
ated a transient burst of hydrogen peroxide, which was the cru-
cial signal for life span extension.59 Whether caloric restriction 
induces increased longevity in much more complex mamma-
lian species as it does in yeast and nematodes is a problem of 
much greater magnitude. In mice, caloric restriction was found 
to influence the expression of more than 3000 genes. Among 
these were ones involved in the mammalian target of rapamy-
cin signal pathway and the NNMT gene. Overall, the change 
in the genetic expression profile in the liver male mice was 
found to gravitate towards that found in female liver. This 
more female expression was suggested to be the mechanism for 
the increased longevity.60 That MeNAM may play a role in 
human longevity is uncertain. Oxidative free radicals are gen-
erally regarded as being disadvantageous in most instances, 
particularly in the brain. In a mouse model of Alzheimer dis-
ease, oxidising free radicals were seen to be part of the disease 
process. Nicotinamide, acting as a reducing agent, mitigated 
the action of the reactive oxygen species.61 Whether NNMT 
and the subsequent conversion of NAM to MeNAM would be 
beneficial is uncertain. Ageing effects on other organs apart 
from the brain will have significant implications for longevity 
also. In the human kidney, ageing was found to increase the 
expression of STAT1 and STAT3 transcription factors. Signal 
transducer and activator of transcription 3 is a potent regulator 
of NNMT expression, as described below,62 and NNMT is 
strongly expressed in the kidney. Thus, numerous organs, in 
addition to the brain, may undergo NNMT-modulated ageing, 
but whether caloric restriction really does influence our ageing 
is far from clear.
NNMT in NAM Catabolism and Phase 2 Catabolism 
of Xenobiotica
Nicotinamide N-methyltransferase acts as the major catabolic 
route for NAM to be excreted from the body. The conversion 
product MeNAM is excreted in the urine or is further oxidised 
to either the 1-methyl-2-pyridone 5-carboxylamide or 
1-methyl-2-pyridone 3-carboxylamide derivatives by aldehyde 
oxidase, and these products are then excreted in the urine.63–65 
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The conversion of NAM to the MeNAM cation led to NNMT 
being classified as a component of the phase 2 clearance system 
for xenobiotica66 because the positively charged ions formed 
are more easily excreted than the parent compound. Studies on 
animal NNMTs indicate that the enzyme has a broad substrate 
range. Mostly, data from studies on activities of nonhuman spe-
cies have been assumed to apply to the human enzyme.67
The actions of phase 2 enzymes are thought to be beneficial, 
but this may not always be the case. An example of this is the 
possible action of NNMT in the central nervous system (CNS), 
in which the enzyme might convert some endogenous amines 
to toxic charged compounds that do not cross the blood-brain 
barrier easily to pass back into the peripheral circulation. In 
accordance with this concept of NNMT being capable of 
methylating a wide range of substrates, we have shown it to be 
able to methylate the nitrogen atom in position 2 of the natu-
rally occurring β-carboline, norharman.68 (It is very likely that 
NNMT was responsible for the N-methylation of pyridine in 2 
human subjects reported by Caldwell et al.69) The specificity 
constant (kcat/Km) for norharman was lower than that of NAM, 
suggesting that NAM is the preferred substrate for NNMT.68
In contrast, these reactions occurring within the liver form 
charged compounds which are excreted or further metabolised 
and then excreted. Any cation so formed is unlikely to cross the 
blood-brain barrier and enter the CNS from the peripheral cir-
culation, and so, the cations are relatively harmless. Methylation 
of these 2 compounds in the brain has an unfortunate result, 
however, in that the compounds formed are neurotoxins and 
they have been suggested to be linked to the Parkinson disease 
because of their ability to inhibit mitochondrial complex I.70 
Nevertheless, the specificity constant and catalysis constant 
(kcat) for norharman are 54-fold and 256-fold lower than for 
NAM, respectively, suggesting that any N-methylation, par-
ticularly in the presence of NAM, will be very low. In addition, 
in vitro studies have demonstrated that 2-methylnorharman 
toxicity is significantly lower than that of its parent com-
pound,68 casting doubt on the possibility that it is a factor in 
the cause of the Parkinson disease.
NNMT as a Regulator of the Actions of NAM and 
NAD+/H
One of the most important functions of NAM is the formation 
of NAD+, which raises the question of what influence, if any, 
NNMT has on NAD+ availability. To address this question, the 
formation of NAD+ and its uses are discussed below.
Nicotinamide, from either the diet or the actions of a variety 
of cellular enzymes, enters the so-called salvage pathway for 
the formation of NAD+. In this, nicotinamide phosphoribosyl-
transferase (NAMPT) converts NAM to nicotinamide mono-
nucleotide (NMN), using phosphoribosylpyrophosphate as the 
phosphoribotide moiety donor, and then 1 of the 3 forms of 
nicotinamide mononucleotide adenosyltransferase (NMNAT) 
converts NMN to NAD+, using ATP as the nucleotide donor 
(Figure 2). Nicotinamide mononucleotide adenosyltransferase 
1 is located in the nucleus, and NMNAT2 is present in cyto-
plasm supplying those sites with NAD+. The origin of mito-
chondrial NAD+ is uncertain. Nicotinamide mononucleotide 
adenosyltransferase 3 has been suggested as the enzyme con-
verting NMN to NAD+ in the mitochondrion,71 but this is 
disputed.72 An alternative explanation for the presence of 
NAD+ in the mitochondrion discussed by Yamamoto et al72 is 
that of the action of hitherto unidentified transporters of the 
dinucleotide from cytoplasm into the mitochondrial matrix.
Once formed, in the mitochondrial matrix, NAD+ is con-
verted to reduced nicotinamide adenine dinucleotide (NADH) 
to either serve as the electron and hydrogen ion donor for com-
plex I or act as the cofactor for enzymes, such as silent informa-
tion regulator 3 (sirtuin 3).73 On leaving the mitochondrion, it 
may be converted into reduced nicotinamide adenine dinucleo-
tide phosphate (NADPH) in the cytoplasm, or it acts as sub-
strate or cofactor for several enzymes in other cellular 
compartments and extracellular enzymes (Figure 2). A list of 
enzymes that consume NAD+ are as follows:
1. CD38 and CD157 (adenosine diphosphate [ADP]-
ribosyl cyclase 2) are located on the plasma membrane 
and convert NAD+ to cyclic adenosine diphosphate 
ribose, the latter acting as a second messenger involved in 
calcium regulation.74
2. Adenosine diphosphate-ribosyltransferases may be 
divided into 2 groups. One group transfers a single ADP-
ribosyl group (a process called MARylation),75 eg, 
2,3,7,8-tetrachlorodibenzo-p-dioxin poly(ADP-ribose) 
polymerase, also known as ARTD14.76 The second 
group comprises several enzymes termed poly ADP-
ribosyltransferases. As the name signifies, they transfer 
multiple ADP-ribosyl groups (PARylation). They are 
involved in a variety of cellular processes,77 eg, DNA 
repair and transcription elongation.78,79
3. Sirtuins, a group of 7 proteins located in cytoplasm 
(sirtuins 1 and 2), the mitochondrion (sirtuins 3, 4, and 
5), or the nucleus (sirtuins 1, 2, 6, and 7). Most of the 
sirtuins deacetylate proteins such as histones involved 
in the regulation of gene expression.80 Some deacylate 
other groups such as malonyl, succinyl, and glutaryl 
residues (sirtuin 5) or long-chain fatty acid residues 
(sirtuin 6). Although deacetylation of histones is a 
prominent feature of sirtuin action, their actions are 
not limited to this. They take part in a variety of intra-
cellular reactions, eg, MARylation and autophagy.75,81 
Sirtuins influence a wide variety of cellular processes. 
These include the following:
(a) Sirtuin 1 – mitochondrial biogenesis, ageing, and 
related diabetic complications82,83;
(b) Mitochondrial sirtuins 3, 4, and 5 – the response to 
oxidative stress, cell cycling, cell viability, and energy 
homeostasis in liver and heart;84–86
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(c) Sirtuin 6 – ageing87;
(d) The NADH diphosphatase, NUDT12, located in 
peroxysomes,88 converts NAD+ to NMN which can 
then exit the organelle and enter the salvage path-
way and in doing so contributes to the NAM pool.
The references mentioned above are mostly detailed recent 
reviews of the specific actions of the enzymes listed. More gen-
eral reviews of the actions of these intracellular enzymes and 
their effects on cellular processes have been written by Opitz 
and Heiland,89 Verdin,90 and Nikiforov et al.91 The consump-
tion of NAD+ and the liberation of NAM by the enzymes are 
illustrated in Figure 2. Interestingly, NAM acts as a potent 
inhibitor of some of these reactions.
The enzymes performing the multifarious reactions cited 
above are all likely to have their own normal ranges of expres-
sion in the various cells of the body and thus different rates of 
NAD+ consumption. Given also that there are differing ranges 
of NNMT expression in cells, the individual organ contribu-
tions to MeNAM serum and urine concentrations are 
smoothed and do not reflect NAM metabolism in any specific 
organ. To a degree, giving a predetermined dose of NAM to 
temporarily fasted subjects overcomes the influence of diet on 
serum and urine measurements; however, complete 24-hour 
urine collections are notoriously difficult to obtain. Clearly, 
biopsy material would be ideal for assessing NAM metabolism 
in specific organs, but this is not readily available in healthy 
individuals. However, in disease states, both serum and tissues 
are available, and in these conditions, NNMT often does play 
an important in modulating NAD+ usage.
Humans on a healthy diet might be expected to have suffi-
cient vitamin B3 in its various forms to ensure that NNMT is 
not the rate-determining factor in the formation of NAD+/H 
for the above reactions. Nevertheless, the fact that NNMT has 
a wide expression range will influence an individual’s daily 
requirement for the vitamin, with high expressors of NNMT 
presumably requiring a higher intake than low expressors. 
From this, it can also been seen that a suboptimal daily intake 
of niacin, as reported for a significant percentage of the general 
population of people aged more than 65 years in the United 
Kingdom,92 could have serious health implications, as reported 
for congenital heart defects in children.30
NNMT and Energy Regulation
The role of NNMT in energy regulation has been studied in 
most detail in the hepatocyte and the white fat cell. In both 
instances, it is the effects on mitochondrial generation of 
energy, the major source of ATP in most cells, that are key, 
rather than glycolysis being key. The NADH is the electron 
and hydrogen donor for complex I; thus, varying levels of 
NNMT have the potential to alter levels of NAM and hence 
NADH directly. Nevertheless, for healthy individuals eating a 
good diet, vitamin B3 intake is probably sufficient to ensure 
that the influence of genetically determined NNMT expres-
sion on NAM catabolism is not a major factor. In undernour-
ished children, however, NNMT expression is thought to 
increase. NNMT expression is an adaptive response to the 
inadequate diet. This further reduces NAM availability for 
energy production. As a consequence, MeNAM excretion in 
the urine is increased. Brazilian children with high MeNAM 
Figure 2. Metabolic pathways of nicotinamide. Arrows: green denotes entry of nicotinamide from diet; red, formation of NAD+; blue and purple, salvage 
pathways to regenerate nicotinamide and nicotinamide mononucleotide; black, nicotinamide catabolic pathways. ADP indicates adenosine diphosphate; 
NAD+, oxidised nicotinamide adenine dinucleotide; NAMPT, nicotinamide phosphoribosyltransferase; NMNAT, nicotinamide mononucleotide transferase; 
NNMT, nicotinamide N-methyltransferase; PARPs, poly ADP-ribosyltransferases.
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urinary excretion were found to have a better catch-up growth 
on refeeding than those with lower MeNAM excretion. It 
was posited that the high urinary MeNAM excretion had 
allowed these children to make a better adaptive response to 
the poor diet.93
The regulation of energy metabolism is subtle and needs to 
respond to demand and variable input from diet as well as the 
constant effect of genetics. Recent evidence has shown that sir-
tuins 1 and 3 are the major regulators of mitochondrial energy 
metabolism and, importantly, that NNMT is central to their 
actions. Factors regulating response of sirtuin 1 to diet, medi-
ated by NAMPT effects on NAD+ synthesis and the actions of 
transcription factors, such as forkhead box protein O (FOXO)-
1, -3, and -4, were reviewed by Chalkiadaki and Guarente94 in 
2011. The following year, actions of sirtuins 1 and 3 were 
reviewed in more detail by Nogueiras et al,95 although any role 
for NNMT was not considered in these reviews. Subsequently, 
Kraus et  al described the effects of NNMT knockdown on 
mice and a high-fat diet on white fat cell metabolism. They 
showed that a high-fat diet increased NNMT expression. 
When they knocked down NNMT expression using antisense 
oligonucleotides, they found that
“NNMT knockdown in adipose tissue and liver protected mice 
from diet-induced obesity, causing a 47% reduction in relative fat 
mass and a 15% increase in relative lean mass.”
These changes were due to increased energy expenditure 
(increased oxygen consumption) rather than reduced food 
intake. This action resulted from the effect of NNMT expres-
sion on polyamine flux. Kraus et al postulated that in the white 
cell, decreased NNMT expression allowed more SAM to be 
‘shunted’ into polyamine metabolism in which polyamines are 
acetylated and then excreted into the urine for further catabo-
lism, thus increasing energy expenditure. The levels of NAD+, 
the cofactor of sirtuin 1, were increased, allowing increased 
expression of the target genes of sirtuin 1. Increased NAD+ was 
also thought to favour increased ATP synthesis, thus allowing 
a further increase in energy expenditure.96
In accordance with these findings on the deleterious effects 
in the white fat cell, NNMT expression was found to be upreg-
ulated in both subcutaneous and omental white fat cells of 
patients with type 2 diabetes. Kannt et al analysed cells from 55 
women and 33 men with type 2 diabetes and compared the 
results with those from 73 women and 38 men without the 
disease. Generally, women tended to have higher results than 
men, and when either of the diabetic sex’s results were com-
pared with the appropriate nondiabetic sex’s results, they were 
found to be significantly higher. Plasma MeNAM concentra-
tion correlated with total white fat NNMT expression in 
patients with diabetes but not in nondiabetic patients.97 In a 
larger study involving 691 men and 469 women, serum 
MeNAM concentration was found to correlate significantly 
positively with body mass index (kg/m2), waist circumference, 
hip circumference, and low-density lipoprotein (LDL) choles-
terol and negatively with high-density lipoprotein cholesterol. 
Serum MeNAM concentration was associated with a high risk 
of obesity (N = 1160, odds ratio of 3.04 with 95% confidence 
interval of 1.61–5.73, and significance of P < .001), further 
emphasising the relationship of NNMT and MeNAM with 
white fat cell metabolism.98,99
In contrast to what happens in the white fat cell, in the liver 
increased NNMT expression was found to have a beneficial 
effect. Again, this was shown by Hong et al100 to occur via the 
effects of NNMT action on sirtuin 1 activity. Prior to the paper 
of Hong et al, increased sirtuin 1 activity was known to upregu-
late gluconeogenesis101–103 and suppress cholesterol synthesis 
and lipogenesis.104,105 Using mice and mouse hepatocytes, 
Hong et al showed that MeNAM mediated all the effects of 
NNMT by stabilising hepatocyte sirtuin 1 protein, so decreas-
ing its catabolism and increasing its half-life, without any effect 
on sirtuin 1 gene transcription. Increased NNMT leading to 
increased sirtuin 1 activity resulted in increased glucose output 
from hepatocytes, and ablation of NNMT synthesis resulted in 
the opposite effects. Importantly, Hong et al showed that their 
mouse in vivo and hepatocyte in vitro results were mirrored in 
humans. They assayed the NNMT mRNA extracted from liver 
biopsy samples by reverse transcription polymerase chain reac-
tion (RT-PCR); serum cholesterol, LDL cholesterol, triglycer-
ides, and glucose by routine clinical biochemical assays; and 
insulin activity by euglycaemic, hyperinsulinaemic clamp 
methodology in samples from 51 obese patients. Hepatic 
NNMT mRNA levels were shown to be significantly posi-
tively correlated with glucose infusion rate and serum cortisol 
and significantly negatively correlated with serum total choles-
terol, LDL cholesterol, and total fasting triglycerides.100
The role of sirtuin 3 in energy metabolism has been reviewed 
in detail by Nogueiras et al95 in 2012. The central role of sirtuin 
3 in the modulating response of hepatocyte mitochondria has 
been further explored by Liu et al.106 They studied the effects 
of fasting in mouse hepatocytes and found that fasting induced 
pronounced transcription of mitochondrial oxidative phospho-
rylation (OXYPHOS)-related genes, with relatively little effect 
on the transcription of nuclear DNA–encoded genes. This 
induction was independent of mitochondrial neogenesis. 
Furthermore, they showed that sirtuin 3 was ‘necessary and 
sufficient’ to mediate this induction. They showed that fasting 
induced glucagon secretion and proposed that this gave rise to 
increased mitochondrial NAD+, which is the cofactor for sir-
tuin 3, allowing increased sirtuin 3 activity. The origins of 
mitochondrial NAD+ are of some debate, but any reduction in 
cytosolic NNMT would increase the availability of NAM for 
NAD+ synthesis, thus implicating NNMT in sirtuin 3’s actions.
Another potential site of NNMT’s action on energy 
metabolism is the brain. Nicotinamide N-methyltransferase 
is expressed in various parts of the CNS, which also expresses 
sirtuins 1 and 3. Nevertheless, the role of NNMT and 
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MeNAM in the normal healthy brain is unclear. Nicotinamide 
N-methyltransferase is increased in the Parkinson dis-
ease,34,107 and MeNAM has been shown to ameliorate some 
of the effects of diabetes in the brain in a rat model,108 
prompting the idea that the increase in NNMT, and conse-
quently MeNAM, is a defensive response to protect neurons. 
The topic of NNMT and energy production is clearly com-
plex. One article comments on NNMT as bad in fat and good 
in liver.109 This complexity is increased by the interplay 
between the mitochondrion and the nucleus in response to 
nutrient availability and stresses of various nature.110,111 
Nicotinamide N-methyltransferase is not always considered 
as a participant in this scenario, although it clearly does have 
a role. Only further research will elucidate this role.
Expression and Actions of NNMT and MeNAM in 
Cancer
The description of overexpression of NNMT in human thy-
roid cancer by the group of Hershman was the first detailed 
report of this phenomenon in cancer.112 This study has been 
followed by reports of the enzyme’s generally increased expres-
sion in a wide range of cancers, with the group of Emanuelli 
being responsible for a significant number of such reports. The 
range of cancers involved is shown in Table 1. Nevertheless, it 
should be remembered that this body of work is a corollary of 
earlier work showing the link between increased MeNAM 
excretion and cancer.131–133 As a phenomenon, the increased 
production of NNMT in this first case prompts 4 questions: (a) 
is it elevated in every cancer, (b) what causes its expression to 
be deregulated, (c) what is the consequence of its deregulation, 
and (d) what use can be made of the phenomenon itself and the 
facts revealed in the answers to questions (a) to (c).
The reasons for the deregulation of NNMT expression in 
cancer are far from clear. Cancers have been postulated to arise 
from transformed stem cells, and the process of transformation 
is one of dedifferentiation. Interestingly, NNMT is said to 
modulate the epigenetic environment in the differentiation 
process in stems cells in the earliest period of human life.51 
Also, in 1 neoplasm, NNMT expression was found to be higher 
in stem cell–enriched cultures of Hep-2 cells (originating from 
cancer of the larynx) compared with the level in cultures of the 
parental cells.134 In view of the above, the increased levels of 
NNMT in cancers may be regarded as playing a role in chang-
ing DNA methylation status, thus favouring a pattern of gene 
transcription more in tune with a dedifferentiated state. In 
addition, 2 of the transcription factors known to regulate 
NNMT expression, STAT3 and TGF-β1 (Figure 3), are highly 
expressed in numerous cancers, including clear cell renal cell 
carcinoma and oral squamous cell carcinoma.125,135 However, 
NNMT expression is not always elevated, as will be shown 
below. Thus, such a simple explanation is difficult to hold. 
Therefore, in an attempt to clarify the ups and downs of 
NNMT expression, the succeeding paragraphs describe factors 
influencing NNMT expression and what are thought to be 
some of the consequences of its expression.
As can be seen from Figure 2, NNMT stands juxtaposed to 
the cascade of NAD+-forming and NAD+-consuming enzymes, 
forming the major catabolic route for NAM. The formation of 
MeNAM in this catabolic route has often been thought to be 
the only function of NNMT, with MeNAM serving as an 
inert, more easily excreted product compared with NAM. 
However, this would be to ignore data evidencing the cell 
growth–promoting properties of MeNAM,131–133 which link to 
earlier data suggesting a relation between NAM methylation 
and cancer.136–138 Nevertheless, even if the biologically inert 
nature of MeNAM were the case, supranormal expression of 
NNMT would have the capability to not only influence NAM, 
NAD+/H, and NADPH levels but also those of SAM, and 
ultimately homocysteine. Thus, NNMT has been envisaged as 
a metabolic sink, its high expression in many cancers resulting 
in lower availability of SAM, as judged by the SAM:SAH 
ratio, and hence hypomethylation of histones.139 (The 
SAM:SAH ratio reflects the ability to methylate DNA at cyto-
sine residues.) This epigenetic modification of DNA (methyla-
tion) tends to downregulate gene transcription.140 The high 
expression of NNMT in cancers may also limit the availability 
of NAM and NAD+ for participation in reactions other than 
DNA methylation, which are illustrated in Figure 2. Thus, 
coupled with changes in the pattern of DNA methylation from 
effects on SAM availability, the effects of increased expression 
NNMT on NAD+ availability and consequently on the actions 
of sirtuins on histone deacetylation and energy metabolism will 
favour carcinogenesis. The above actions might be relatively 
unimportant if NNMT expression was high in only a limited 
number of rare cancers, but this is not the case. Nicotinamide 
N-methyltransferase is highly expressed in a wide range of can-
cers, as illustrated in Table 1. This shows that NNMT expres-
sion is elevated in cancers in several different areas of the body 
and includes most of the common human malignancies. The 
question then arises as to what part NNMT plays in the pro-
cess of carcinogenesis. The possibilities of the increased 
NNMT are as follows: a cause of carcinogenesis, a supportive 
consequence of carcinogenesis, an irrelevant consequence, and 
an anticarcinogenic reaction of the cell. The available data tend 
to favour the second option – a consequence supportive of car-
cinogenesis – because of increased NNMT and MeNAM 
support:
1. Increased mitochondrial ATP synthesis141,142;
2. Increased cell replication143;
3. Increased cell migration and metastatic invasion of 
tissues.144,145
The following paragraphs concentrate on the effects of 
increased expression because this is the more common phe-
nomenon, but it should be remembered that this does not occur 
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in every cancer. Furthermore, it does not occur in every indi-
vidual patient, even though in a group of such cases, its median 
level of expression is elevated.
Increased NNMT Expression and ATP Synthesis in 
Cancer
To illustrate point (1), we transfected NNMT into SH-SY5Y 
cells (human neuroblastoma) which do not express the enzyme. 
The transfected cells had significantly decreased cell death 
compared with that seen in wild-type cells. This decrease was 
correlated with increased intracellular ATP content, ATP:ADP 
ratio, and complex I activity and a reduction in the degradation 
of the NDUFS3 (NADH dehydrogenase (ubiquinone) iron-
sulphur protein 3) subunit of complex I. These effects were 
replicated by incubation of SH-SY5Y cells with MeNAM, 
strongly suggesting that MeNAM mediated the cellular effects 
of NNMT. Furthermore, expression of NNMT in SH-SY5Y 
cells significantly increased the expression of sirtuins 1, 2, and 
3. Small interfering RNA–mediated silencing of sirtuin 3 
expression decreased complex I activity in NNMT-expressing 
SH-SY5Y cells to that observed in wild-type SH-SY5Y and 
significantly reduced cellular ATP content.141,142 Although in 
vivo cancer cells undergo a shift away from mitochondrial 
OXYPHOS and towards glycolysis as their source of ATP,146,147 
the presence of higher than normal levels of MeNAM may 
help to maintain a level of OXYPHOS in the changed envi-
ronment of rapidly dividing cells. In view of the fact that mito-
chondria are generally similar throughout the human body, this 
effect of MeNAM on OXYPHOS may occur in all types of 
cancer in which increased expression of NNMT occurs. 
Whether the result of high NNMT expression is benign is less 
certain. Although OXYPHOS was found to be higher in 
PANC-1 cells expressing the enzyme compared with ones not 
doing so, the NNMT-expressing cells were more resistant to 
glycolytic inhibition and they had greater cell migration and 
invasion capacities.148 These findings contrast with the find-
ings of Capello et al147 who found that silencing alpha enolase 
expression restored OXYPHOS and induced cell growth arrest 
in a variety of cancer cell lines.
In contrast to the idea that the level of NNMT expression 
is always increased in cancer, Yamada et al explored the effect 
interferon gamma on NNMT in glioma. Treating the cancer 
with interferon gamma resulted in increased NNMT activity 
and hence MeNAM levels, but not NNMT expression. They 
also treated these cells with MeNAM. Neither treatment 
affected intracellular NAD+ levels or cell viability. As a con-
sequence, they questioned the idea that increased NNMT in 
cancer always reduced cellular NAM concentration in 
tumour cells.149
Increased Expression of NNMT Generally Favours 
Increased Cell Replication, Cell Migration, and 
Metastatic Invasion
The evidence for NNMT and MeNAM increasing cell prolif-
eration is mixed. Early reports indicate that MeNAM supports 
cell replication.131–133 In addition, some recent authors report 
data that support the contention. Later data come from trans-
fection experiments using model cell systems. Thus, Yu et al148 
state that NNMT overexpression in PANC-1 cells (a pancre-
atic tumour cell line) promoted cell proliferation, whereas 
NNMT knockdown with silencing mRNA reduced prolifera-
tion. Xie et al150 using colorectal cells (human colorectal cancer 
cells line SW480), Zhang et  al151 using Bcap-37 and 
MDA-MB-231 breast cancer cell lines, and Sartini et  al120 
using lung cells (human lung cancer cell line A549) reported 
similar findings. Wu et al conducted a survey of results from 40 
human bladder cancer cell lines to identify factors influencing 
cell migration. The results were used to assay tumour stage in 
61 patients. Together, these analyses identified metallothionein 
1E and NNMT as being significantly positively correlated 
with cell migration and tumour stage.145
Regarding other markers of tumorigenicity, Xie et  al150 
reported that NNMT overexpression enhanced colony forma-
tion in vitro and tumorigenicity in mice and inhibited apopto-
sis and promoted cell cycle progression, MeNAM alone 
producing similar results. Knockdown of NNMT in the lung 
cell model had the reverse effect, in that colony formation was 
inhibited.120 Similarly, reduction in the expression of NNMT 
in breast cancer cells caused reduced expression of Bcl-2 and 
Bcl-xL and decreased phosphorylation of protein kinase B 
(Akt) and extracellular signal–regulated kinase 1/2 (ERK1/2). 
Together with the upregulation of Bax, Puma, cleaved caspase 
9, cleaved caspase 3, and cleaved poly ADP-ribosyltransferase, 
these data indicated the downregulation of NNMT-induced 
apoptosis via the mitochondrial pathway.151
Figure 3. factors influencing NNMT expression and results associated 
with NNMT expression in cancer. Akt indicates protein kinase B; c-Jun, 
Jun transcription factor; ERK1/2, extracellular signal–regulated kinases 1 
and 2; HNf-1β, hepatic nuclear factor-1β; IGf, insulin-like growth factor; 
MeNAM, 1-methylnicotinamide; NNMT, nicotinamide N-
methyltransferase; SAH, S-adenosyl homocysteine; SAM, S-adenosyl 
methionine; SH, sonic hedgehog; STAT3, signal transducer and activator 
of transcription 3; TGf-β1, transforming growth factor β1.
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Further evidence of the involvement of the phosphoinositide 
3-kinase/Akt pathway in tumorigenicity comes from the work 
of Wu et al. They showed that there were positive correlations 
between NNMT and NNMT and matrix metallopeptidase-2 
(MMP-2) in clear cell renal cell carcinoma cell lines and clini-
cal tissues.145 Matrix metallopeptidase-2 is a member of a fam-
ily of 23 such enzymes which are responsible for turnover of 
extracellular matrix by proteolytic degradation.152 Inhibition of 
MMP-2 significantly suppressed NNMT-dependent cellular 
invasion in HEK293 cells. In vivo ‘knockdown of NNMT 
expression efficiently inhibited the growth and metastasis of 
clear cell renal cell carcinoma cells in non-obese diabetic severe 
combined immunodeficiency mice’.144
In contrast to the above, the effects of increased MeNAM 
and NNMT on cancer are more complex than simply increas-
ing proliferation and turmorigenicity. In fact, their effects dif-
fer depending on the cancer. Hence, Sartini et al124 report that 
in oral squamous cell carcinoma, NNMT upregulation cor-
relates inversely with lymph node metastasis. This was fol-
lowed by reports from the same group that (a) upregulation of 
the enzyme correlated positively with the differentiation state 
of the cancer125 and (b) knockdown of the enzyme reduced 
proliferation in the human oral squamous cell carcinoma cell 
line, KB.153 Zhou et  al also reported data that support the 
concept that NNMT expression in not necessarily deleteri-
ous. They found that NNMT was highly expressed in only 
64.2% (77 of 120) of their cases, but as high as 83.3% in high-
grade prostatic intraepithelial neoplasia, and that NNMT 
expression was a positive prognostic indicator of survival in 
prostate cancer.130
In accordance with the findings on oral squamous cell car-
cinoma, Blazejczyk et  al report that MeNAM and its ana-
logue, 1,4-dimethylpyridine, inhibited metastasis formation 
in the lung in a mouse model of mammary cancer. They 
showed that this effect of the 2 compounds was enhanced 
when they were administered with cyclophosphamide. They 
proposed that MeNAM acted via significantly increasing 
prostacyclin GI2 activity.154
Factors Influencing and Influenced by NNMT 
Expression in Cancer
Four important transcription factors have been shown to have 
a significant role in modulation of NNMT expression. These 
are hepatocyte nuclear factor-1β in papillary thyroid cancer,20 
STAT3 in colon adenocarcinoma,21 and sonic hedgehog ligand 
in pancreatic cancer.155 In contrast to these 3 examples, where 
NNMT is elevated, the reduction in NNMT expression in 
insulinoma cells was shown by Nabokikh et al22 to be corre-
lated with reduced TGF-β1 expression. A detailed example of 
this relationship between a transcription factor and NNMT 
expression is explained below:
“We observed there was enhanced expression of NNMT in cyto-
plasm of 76 (86%) colon adenocarcinoma tissues among 
88 evaluable samples. On the other hand, 16 of 17 normal colon 
tissues were weakly stained with NNMT antibody by immunohis-
tochemistry. Of the 88 cancer tissues, 66 (75%) were positive for 
phosphorylated STAT 3 (tyrosine 705) antibody, whereas all nor-
mal tissues were almost negative. Of the 66 nuclear phosphoryl-
ated STAT 3–positive cases, 61 (92%) were also strongly stained 
with anti-NNMT antibody. These results showed that enhanced 
expression of NNMT was correlated with activation of STAT 3 
(P < 0.001).”21
Clearly, all 4 of these factors are unlikely to be acting in all 
cancers, and other transcription factors may well be acting in 
cancers other than those cited above. Nevertheless, the impor-
tant feature of the increased expression of NNMT in most 
cancers is most likely due to increased transcription rather than 
any effect on catabolism. The reduced expression in insulinoma 
and colorectal carcinoma would seem to add support to this 
idea. Furthermore, many of the effects of increased NNMT 
expression appear to be mediated by increased synthesis of 
MeNAM.
Another factor influencing expression in a cell model was 
investigated by Bi et al. They explored the relationship between 
PANC-1 cells expressing a gain-of-function noncoding micro-
RNA-1291 (miR-1291) and control PANC-1 cells. The for-
mer cells expressed significantly higher mounts of NNMT and 
MeNAM than control cells. In a xenograft model where nude 
mice were injected with either miR-1291 PANC-1 or control 
PANC-1 cells, NNMT expression was greater in the animals 
receiving the miR-1291 PANC-1 cells, and tumour size and 
weight were less, resulting in NNMT levels being inversely 
correlated with tumour size.156
Other Effects of Increased NNMT Expression
One of the consequences of increased NNMT expression is 
reported to be increased resistance to the effects of radiation. 
This was reported to occur in cancer stem cells by D’Andrea 
et  al157 who studied 2 mesenchymal stem cell clones, one 
expressing NNMT and the other not, in a model of Ewing 
sarcoma. Ewing sarcoma is the second most common bone 
cancer in children. It is a high-grade malignancy in which 
25% of patients are metastatic at presentation and which has 
a very poor prognosis. It grows rapidly and metastasises to 
lungs and bones. The NNMT-expressing cells were found to 
have greater resistance to radiation. D’Andrea158 postulated 
that the increased NNMT activity resulted in lower intracel-
lular NAM levels, thus limiting DNA repair by PARP1, 
which uses NAM as a cofactor. This complements earlier 
work by Kassem et  al,159 who found that NNMT helps to 
predict the response to radiation in bladder cancer. Knockdown 
of NNMT in a glioma cell line (U87) also rendered the cells 
more susceptible to radiation.36
Nicotinamide N-methyltransferase expression has been 
found to be related to drug resistance. Hsu et al160 related the 
resistance of 78 cancer cell lines to 99 drugs and found that 8 
genes (EGFR, ITGA3, MYLK, RAI14, AHNAK, GLS, IL32, 
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and NNMT) showed significant gene-drug correlation with 
paclitaxel, docetaxel, erlotinib, everolimus, and dasatinib. In 
contrast to the above, where NNMT expression has been 
related to resistance to therapeutic agents, 1 group reports a 
beneficial effect. Kwon et al studied the actions of sulphona-
mide analogues of antofine and cryptopleurine. They proposed 
that the inhibited growth of Caki-1 renal cancer cells seen after 
exposure to one of the sulphonamide cryptopleurine analogues 
occurred via the action of NNMT-dependent c-Jun N-terminal 
kinase activation on G0/G1 cell cycle arrest.161
NNMT as a Biomarker in Cancer
As can be seen from Table 1, NNMT is upregulated in a 
wide range of cancers, and the authors of these reports gen-
erally postulate the idea that NNMT could function as a 
valuable biomarker. Precisely, how NNMT assay might be 
used as a biomarker differs with each cancer. As a minimally 
invasive screening tool, serum or plasma NNMT concentra-
tion would be a sum of NNMT released by the cancer and 
that released into the circulation from the liver. Given that 
(a) NNMT expression in healthy livers is higher than in 
other organs and (b) most cancers are small compared with 
the liver, one might expect that NNMT release from the can-
cer might have little impact on circulating concentration. 
Circulating MeNAM concentration may have similar con-
tributions from liver and the cancer in some circumstances, 
but there would be further variations because of differences 
in diet, making circulating MeNAM concentrations difficult 
to interpret in theory. Nevertheless, NNMT has been sug-
gested as a biomarker in fluids, and where it has been sug-
gested as such is reviewed below.
As an identification, classification, and prognostic tool, the 
assay of NNMT in the cancer tissue compared with that in 
nonmalignant tissue, in theory, offers more promise than blood 
and other biofluid concentrations. Although NNMT expres-
sion is upregulated in many cancers, it is not upregulated in all 
cancers. To address the problems associated with the use of 
NNMT as a biomarker in tissues, the literature concerning the 
following 4 cancers is reviewed in detail: renal cell carcinoma, 
glioma, oral squamous cell carcinoma, and hepatocellular carci-
noma. Other cancers where deregulation of NNMT expression 
occurs are summarised in Table 1.
The following sections review the latest data on the use of 
NNMT and MeNAM as biomarkers in serum and plasma and 
in tissue samples. These sections are placed in the context of 
early data on these topics.
Early Evidence of Deregulation of NNMT
There are 2 early reports of the quantification of MeNAM in 
cancer or cancer-related activity – by Kerr et  al in 1965 and 
Basu et al in 1973. Kerr et al162 reported that smoking caused 
an approximately 30% fall in MeNAM excretion, and excretion 
rose on cessation of the activity. Basu et al found that MeNAM 
excretion rates in their cancer patients (mean 2.7 mg/g 
creatinine; range: 0.4-3.0, N = 58) were significantly lower than 
those of healthy patients (mean 9.0 mg/g creatinine; range: 
3.8-11.2, N = 15) and those of patients who were ill due to 
nonmalignant causes (mean 8.1, range: 2.1-18.47 mg/g creati-
nine, N = 18).163 Their data indicate that NNMT activity was 
reduced in patients with cancer, probably due to their extensive 
treatment. These reports contrast with later ones describing 
patients at presentation and were made before efficient NNMT 
antibodies, which allow accurate assay of the enzyme’s expres-
sion, became available.
NNMT as a Diagnostic and Prognostic Biomarker 
– Use of Biofluids
Roessler et al used 2-dimensional electrophoresis and protein 
mass spectrometry to identify proteins which were differen-
tially expressed in colorectal cancer tissues compared with lev-
els in normal bowel tissue. One of the proteins identified was 
NNMT. From there, they developed an immunoassay for the 
protein. In the serum samples of normal healthy individuals (N 
= 317), they reported a median NNMT concentration of 308 
ng/L and a range of 146 to 2625 ng/L compared with that of 
109 patients with cancer, who have a median NNMT concen-
tration of 925 ng/L and a range of 169 to 2625 ng/L. They 
postulated that serum NNMT concentration was a promising 
biomarker for colorectal cancer.116 In contrast, Bünger et al164 
also compared serum NNMT concentrations of 164 patients 
with colon cancer, 34 patients with adenoma, and 119 healthy 
subjects and found that serum NNMT concentration was not 
a particularly useful marker.
Tomida et al compared serum NNMT and carcinoembry-
onic antigen (CEA) concentrations as diagnostic biomarkers in 
patients with non–small cell lung cancer – 50 with non-neo-
plastic lung disease and 24 healthy donors – to evaluate the 2 
protein concentrations as minimally invasive diagnostic assays. 
Concentrations were determined by enzyme-linked immuno-
sorbent assays. Areas under the receiver operating characteris-
tic curves for the 2 proteins were 0.703 for NNMT and 0.621 
for CEA. With a specificity of 90%, the sensitivities for NNMT 
and CEA were 25% and 24%, respectively. There was no cor-
relation between the CEA and NNMT concentrations, and 
combining the 2 parameters increased sensitivity.42 In another 
study by Ujiie et al, although serum NNMT concentration was 
found to be elevated in non–small cell lung cancer, as a prog-
nostic guide, serum NNMT proved not to be useful. They fol-
lowed 107 patients over a period of 200 days and found that 
patients with NNMT concentrations less than 710 ng/L (N = 
82) had similar survival rates compared with patients with 
serum concentrations equal or greater than 710 ng/L.165
Using a combination of NNMT, L-Plastin (LPC1), and 
nonmetastatic cell 1 protein (NM23A) plasma concentrations 
in a 3-marker assay for the diagnosis of renal cancer, Su Kim 
et  al found that this combination had a sensitivity of 95.7% 
(specificity 90%) as opposed to 71.9% for NNMT alone. The 
diagnostic accuracy of the combination was 0.932 (positive 
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predictive value, 87.2%; negative predictive value, 97%). In 
these patients, median plasma NNMT concentration was 68 
ng/L (95% range, 54.8-83.2; N = 102) for a control group of 
mainly healthy individuals compared with 420 ng/L (332.6-
511.8, N = 87) for patients with renal cancer. When the perfor-
mance of NNMT alone was compared with the 3-assay 
combination, the sensitivities were for clear cell carcinoma 93% 
(83 of 89 cases) compared with 96% (85 of 89 cases), for papil-
lary carcinoma 100% (6 of 6 cases) compared with 100%, and 
for chromophobe carcinoma 86% (6 of 7) compared with 86%, 
the diagnostic cutoff level being 147 ng/L. When cancer stag-
ing was considered, the results for NNMT assay were similar to 
those of the combination.166
Elevated levels of NNMT in 4 other biofluids were identi-
fied and suggested as possible diagnostic and/or prognostic 
indicators. These were (a) urine for bladder cancer,114 (b) pan-
creatic juice for pancreatic cancer,128 (c) saliva for oral cancer,167 
and (d) interstitial fluid for clear cell renal cell carcinoma.168 
The numbers of patients investigated in these 4 studies were 
relatively small, making any assessment of assaying NNMT as 
a biomarker difficult.
It can be seen from the above that (a) the estimates of 
NNMT concentration in serum and plasma vary quite widely 
and (b) in patients with colorectal cancer the usefulness of 
serum/plasma NNMT estimation as a diagnostic tool is dis-
puted. To clarify these diverse positions, a recognised standard 
NNMT preparation and multicentre trials are required.
NNMT as a Diagnostic and Prognostic Biomarker 
– In Tissue Samples
Renal cell carcinoma
Of all the investigations where NNMT in cancer is the primary 
topic, probably the most investigated cancer is renal cell carci-
noma. Since 2005, following papers by Yao et al169 and Jones 
et al,170 a further 12 papers have been published on the subject 
of NNMT as a biomarker, with the authors using a variety of 
methodologies to explore expression in cancerous tissue. Yao 
et  al using high-density oligonucleotide microarrays explored 
gene expression profiles of 33 renal cell carcinomas, the results 
of which were compared with those of 9 normal kidney tissue 
samples. Nicotinamide N-methyltransferase and adipose differ-
entiation–related protein were found to be upregulated.169 
Using a different technique (immunohistochemistry), Zhang 
et  al171 examined one specific type of renal cancer (clear cell 
renal cell carcinoma, N = 74) and found that elevated NNMT 
levels were a significant prognosticator, high levels indicating a 
worse prognosis. Using yet another technique (mass spectrome-
try–based proteomic analysis, in which proteins separated by 
2-dimensional electrophoresis are identified by mass spectrom-
etry), Teng et al compared protein expression in clear cell renal 
cell carcinoma tissue with that of adjacent normal tissue. This 
comparison of tissues from the same patient confirmed that 
NNMT expression was elevated.172 Similar results (high 
NNMT expression) were found by (a) Girgis et al173 using mul-
tilevel whole-genome analysis, (b) Atrih et al174 using quantita-
tive proteomics, (c) Zaravinos et al,175 and (d) Eikrem et al.176 
These last authors extracted mRNA from formalin-fixed tis-
sues before performing transcriptome sequencing.
Using data from previous studies, Moffitt et  al applied a 
bioinformatics approach to select the most reliable biomarkers 
for clear cell renal cell carcinoma. They claimed that assess-
ment microarray data in the presence of artefacts using caCOR-
RECT2 program gave results of greater accuracy and reliability. 
Their judgement was that NNMT was 1 of 2 genes that were 
the most reliable diagnostic indicator of clear cell renal cell car-
cinoma, the other gene being PRKAB1.177 Use of the Ingenuity 
Pathway Analysis program to analyse data sets for genes dereg-
ulated in clear cell renal cell carcinoma revealed a number of 
transcription factor genes in the top 1% of genes deregulated.175 
Among these was the STAT3 gene, a transcription factor 
known to influence NNMT expression.21 A further develop-
ment was that made by Wozniak et al. These authors compared 
the methylation status of the NNMT gene in clear cell renal 
cell carcinoma with that in adjacent normal tissue. Genome-
wide gene expression profiling was performed on 148 clear cell 
renal cell carcinoma tissue samples from patients in the Czech 
Republic. Not only was NNMT mRNA levels found to be 
elevated but also the NNMT gene was found to be hypometh-
ylated in the cancer tissue,178 which would help to explain the 
increased expression of the protein. Interestingly, in an earlier 
report by Cifola et al179 on increased incidences of loss of het-
erozygosity and variations in copy number, they found that 
alterations in CN occurred quite frequently in chromosome 
11q22 region but not in the 11q23 region where the NNMT 
gene is sited. A similar result (ie, no genetic aberration in renal 
cell carcinoma) was reported subsequently by Arai et al.180
As an assessment tool in cancer staging NNMT was found 
to be modestly elevated in stages 1 to 3 of clear cell renal cell 
carcinoma; however, in stage 4 and in metastases, NNMT was 
highly elevated, in accordance with reports cited above of 
NNMT protein being involved in increased cellular repro-
duction and invasion by cancer cells.181 When NNMT 
mRNA expression levels were assayed in 17 individual clear 
cell papillary renal cell carcinomas, 15 individual clear cell 
renal cell carcinomas, and 13 papillary renal cell carcinomas, 
clear cell renal cell carcinomas were found to have signifi-
cantly higher levels than papillary renal cell carcinomas, with 
clear cell papillary renal cell carcinomas having levels that 
were between the other two.182
Alongside the interest in NNMT in clear cell renal cell 
carcinoma, NNMT features as a potential biomarker in sev-
eral other cancers because of deregulated NNMT expression. 
The relevant papers are summarised in Table 1. Nevertheless, 
4 other areas of interest are dealt with in some detail here. 
These are oral squamous cell carcinoma, prostate cancer, gli-
oma, hepatocellular carcinoma, and insulinoma. In the first 
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two of these, NNMT is generally elevated, but in the last two, 
NNMT expression is reduced in comparison with nonmalig-
nant tissue.
Glioma
Numerous attempts to identify and classify gliomas using 
wide-ranging transcriptome analysis techniques have been 
attempted; however, NNMT did not feature in the results in 
any of these until the report of Li et al in 2009. After examin-
ing both their own material (159 samples) and data from 2 
external data sets (341 patients), they were able to distinguish 
6 subgroups of gliomas. Although NNMT was only briefly 
mentioned even in this report, they concluded that NNMT 
was significantly more highly expressed (approximately 5-fold) 
in glioblastoma-rich groups compared with oligodendro-
glioma-rich groups.118
In accordance with the above finding in glioblastoma, 
Thirumoorthy et  al36 found that NNMT expression was 
higher in primary glioblastoma cell cultures than in estab-
lished cell lines. Interestingly, although Yamada et al also con-
firmed the high levels of NNMT in glioblastoma, they found 
that the high levels of MeNAM had no effect on cell viability 
or on intracellular NAD+ and NAM concentrations. In addi-
tion, they observed that treatment with interferon gamma 
increased NNMT activity but not its protein concentra-
tion.149 A further curiosity revealed by Kiprianova et  al is 
that sorafenib, a drug used in the treatment of recurrent 
or progressive malignant glioma,183 sensitises the cells to 
small-molecule inhibitors of Bcl-2–like proteins in a STAT3-
dependent manner.184 Signal transducer and activator of 
transcription 3 is a transcription factor known to upregulate 
NNMT expression and that its activation is a major factor in 
tumour malignancy.185–188
Oral squamous cell carcinoma
Sartini et  al were first to give a detailed account of NNMT 
upregulation in oral squamous cell carcinoma. Using RT-PCR 
and real-time quantitative PCR on cancerous and adjacent 
normal mucosa, they found that NNMT mRNA was more 
highly expressed. Nevertheless, in contrast to what may be seen 
in clear cell renal cell carcinoma, high expression was found in 
cancers from patients with the more favourable outcome. Little 
difference was found in NNMT expression when levels in can-
cerous tissue and normal mucosa from patients with a less 
favourable outcome were compared. Thus, NNMT expression 
was inversely correlated with the presence of lymph node 
metastases.124 In accordance with these findings, cancers exhib-
iting high NNMT expression were more differentiated than 
ones with low expression.125 Later, however, although high 
NNMT expression was linked to a more favourable outcome, 
cancer stem cells were found to have high expression,134 and 
downregulation of NNMT by silencing mRNA reduced 
tumourigenicity both in in vitro and in vivo mouse assays.189 
Interestingly, NNMT expression also correlates inversely with 
prolonged progression-free and overall survival times in pros-
tate cancer.130 A further variation on the theme of NNMT 
expression may be seen in oral cancers likely resulting from 
chewing tobacco. Here, high expression was found in only 
approximately 50% of cases.190
Hepatocellular carcinoma
Nicotinamide N-methyltransferase is one of many genes that 
have been shown to be differentially regulated in hepatocellular 
carcinoma. Studying data amassed previously from large-scale 
studies contained in libraries, such as the Encyclopedia of 
Hepatocellular Carcinoma genes Online, and from reports by 
individual groups of authors191,192 and from their own investi-
gation, Hsu et al concluded that NNMT mRNA levels were 
downregulated in hepatocellular carcinoma.193 Nevertheless, in 
a later study, Kim et al concluded from studying 120 cases of 
hepatocellular carcinoma at different stages that although 
NNMT expression may be lower in cancer than noncancerous 
tissue, relatively high NNMT mRNA expression was corre-
lated with poor prognosis and a significantly shorter disease-
free survival time (P = .016).119 A further confounding factor in 
the interpretation of NNMT levels arises from the cause of the 
carcinoma. Infection with either hepatitis B virus or hepatitis 
C virus is a serious predisposing factor. Iizuka et al194 showed 
that cancers resulting from infection with hepatitis B virus had 
lower levels of NNMT mRNA expression than patients whose 
cancers resulted from hepatitis C virus infection.
Conclusions
The dominant position of NNMT in NAM metabolism in 
humans was demonstrated by Mrochek et al as early as 1976. 
Initially, patients with schizophrenia were shown to have 
metabolic profiles little different from those of healthy sub-
jects. Having established this, they fed 10 patients (1 healthy 
individual and 9 patients with schizophrenia) graded doses 
(100-3000 mg) of NAM and assayed 24-hour urine output 
of a range of metabolites (NAM, MeNAM, NAM-N1- 
oxide, N1-methyl-2-pyridone-5-carbamide, N1-methyl-4-
pyridone-3-carbamide). At the highest dose of NAM after 24 
hours, on average, approximately 44% of the ingested dose 
was recovered. Methylated metabolites formed 78% of 
recovered compounds, whereas nonmethylated compounds 
(NAM-N1-oxide 13% and NAM 9%) formed only 22% of 
compounds recovered in the urine.195
Research into the biochemistry and physiology of NNMT 
over the following decades has followed a number of recurring 
themes, from the early characterisation of NNMT’s substrate 
specificities by Alston and Abeles67 in 1988 working on the 
porcine enzyme, through Rini et al37 a few years later exploring 
the human enzyme, to the latest report of van Haren et al,196 
who also characterised a similar range of substrates in great 
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detail. The idea that NNMT may be linked to the availability 
of methyl groups in vivo has developed from the early work of 
Kang-Lee et al,197 who studied the effects of increasing doses 
of NAM in rats fed a casein diet, to the proposition of 
Ulanovskaya et al,139 that NNMT created a metabolic sink for 
methyl groups in cancer. As a consequence of these recurring 
themes, the concept of NNMT has developed from that of 
being merely a phase 2 enzyme to one that is capable of shap-
ing the destiny of the human from its earliest phase of life by 
modulating its epigenetic landscape.50 Regarding the expres-
sion of NNMT in cancer, it is clear that in most of the cancers 
studied, NNMT expression is generally increased. Nevertheless, 
it is important to note that this increase does not occur in all 
cancers and neither does it occur in all individual patients even 
though the mean level of expression of a group of such patients 
is high. Furthermore, the effect of an increased expression in 
the malignant tissue is variable. In some cases, increased 
NNMT expression is associated with a more aggressive pheno-
type, and in other cases, this is not so. Whether a therapeutic 
use can be made of increased NNMT expression remains an 
underexplored area. One report has been published on the use 
of a pharmaceutical to interfere with expression – depsipeptide 
interaction with the HNF-1β response element in the NNMT 
gene promoter by Xu and Hershman198 – but this was some 10 
years ago. Another group in 2010 demonstrated the variable 
expression of NNMT in a human rhabdomyosarcoma cell line 
in response to different insulin-like growth factor I receptor 
antagonists.199 This work increased the range of factors influ-
encing NNMT expression, together with the effects associated 
with NNMT expression in cancer, which is illustrated in Figure 
3. Since then, nothing on this topic has emerged. Whether this 
is because the topic has been explored and found to be unprof-
itable or has not been an area of research is unclear. In conclu-
sion, it can be seen that much has emerged to reshape our 
concept of the function of NNMT, but numerous unanswered 
questions still exist.
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